A real-world study of Afatinib plus ramucirumab in treatment-naïve, EGFR-mutated, non–small cell lung cancer

被引：0
|
作者：
Chun-Yao Huang
Hui-Li Huang
Chou-Chin Lan
Yi-Chih Huang
Yao-Kuang Wu
机构：
[1] Taipei Tzu Chi Hospital,Division of Pulmonary Medicine
[2] Buddhist Tzu Chi Medical Foundation,undefined
来源：
BMC Cancer | / 23卷
关键词：
Afatinib; Ramucirumab; Non–small cell lung cancer; mutation;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
    Satoshi Igawa
    Taihei Ono
    Masashi Kasajima
    Seiichiro Kusuhara
    Sakiko Otani
    Tomoya Fukui
    Masanori Yokoba
    Masaru Kubota
    Masato Katagiri
    Hisashi Mitsufuji
    Jiichiro Sasaki
    Katsuhiko Naoki
    [J]. Investigational New Drugs, 2020, 38 : 1906 - 1914
  • [22] Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations
    Chen, Chi-Han
    Chang, John Wen-Cheng
    Chang, Ching-Fu
    Huang, Chen-Yang
    Yang, Cheng-Ta
    Kuo, Chih-Hsi Scott
    Fang, Yueh-Fu
    Hsu, Ping-Chih
    Wu, Chiao-En
    [J]. ANTICANCER RESEARCH, 2022, 42 (04) : 2145 - 2157
  • [23] Real-world assessment of afatinib for patients with EGFR-positive non-small cell lung cancer
    Igawa, Satoshi
    Ono, Taihei
    Kasajima, Masashi
    Kusuhara, Seiichiro
    Otani, Sakiko
    Fukui, Tomoya
    Yokoba, Masanori
    Kubota, Masaru
    Katagiri, Masato
    Mitsufuji, Hisashi
    Sasaki, Jiichiro
    Naoki, Katsuhiko
    [J]. INVESTIGATIONAL NEW DRUGS, 2020, 38 (06) : 1906 - 1914
  • [24] Rociletinib in EGFR-Mutated Non-Small-Cell Lung Cancer
    He, Yong
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (06): : 578 - 578
  • [25] Afatinib as first-line treatment in patients with EGFR-mutated non-small cell lung cancer in routine clinical practice
    Brueckl, Wolfgang M.
    Reck, Martin
    Griesinger, Frank
    Schaefer, Harald
    Kortsik, Cornelius
    Gaska, Tobias
    Rawluk, Justyna
    Krueger, Stefan
    Kokowski, Konrad
    Budweiser, Stephan
    Ficker, Joachim H.
    Hoffmann, Christopher
    Schueler, Andrea
    Laack, Eckart
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [26] Furmonertinib plus icotinib for first-line treatment of EGFR-mutated non-small cell lung cancer
    Chen, H.
    Lin, M.
    Jiang, J.
    Liu, M.
    Lai, Z.
    Luo, Y.
    Ye, H.
    Chen, H.
    Yang, Z.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (04) : S55 - S55
  • [27] A Single-Institution Experience of Afatinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer
    Minemura, Hiroyuki
    Yokouchi, Hiroshi
    Hirai, Kenichiro
    Koizumi, Tatsuhiko
    Kanazawa, Kenya
    Tanino, Yoshinori
    Munakata, Mitsuru
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1230 - S1231
  • [28] When to add anti-angiogenesis drugs to EGFR-mutated metastatic non–small cell lung cancer patients: a real-world study from Taiwan
    Chieh-Lung Chen
    Sing-Ting Wang
    Wei-Chih Liao
    Chia-Hung Chen
    Chih-Yen Tu
    Hung-Jen Chen
    Te-Chun Hsia
    Wen-Chien Cheng
    [J]. BMC Cancer, 22
  • [29] MET overexpression correlated with prognosis of EGFR-mutant treatment-naïve advanced lung adenocarcinoma: a real-world retrospective study
    Wang, Na
    Zhang, Yuan
    Wu, Junhua
    Zhu, Yili
    Wu, Ying
    Huang, Bo
    Zhang, Ruiguang
    Fan, Jun
    Nie, Xiu
    [J]. CLINICAL & TRANSLATIONAL ONCOLOGY, 2024, 26 (07): : 1696 - 1707
  • [30] Real-world outcomes of osimertinib (Osi) vs. afatinib or erlotinib in patients with classical vs. atypical EGFR-mutated metastatic non-small cell lung cancer (mNSCLC).
    Barsouk, Adam
    Elghawy, Omar
    Heidlauf, Alec
    Yu, Connie
    Yang, David
    Kurian, Martin
    Goel, Keshav
    Rushkin, Lynn
    Huang, Anran
    Voruganti, Teja
    Sun, Lova
    Singh, Aditi Puri
    Cohen, Roger B.
    Aggarwal, Charu
    Marmarelis, Melina Elpi
    Langer, Corey J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345